S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:LEXX

Lexaria Bioscience Stock Forecast, Price & News

$6.77
-0.07 (-1.02 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.62
$6.82
50-Day Range
$5.39
$7.02
52-Week Range
$3.98
$12.50
Volume67,489 shs
Average Volume769,145 shs
Market Capitalization$34.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
30 days | 90 days | 365 days | Advanced Chart
Receive LEXX News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.


About Lexaria Bioscience

Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LEXX
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
$380,000.00
Book Value
$0.83 per share

Profitability

Net Income
$-4.09 million
Net Margins
-432.69%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$34.55 million
Next Earnings Date
10/20/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.29 out of 5 stars

Medical Sector

1317th out of 1,361 stocks

Pharmaceutical Preparations Industry

646th out of 668 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












Lexaria Bioscience (NASDAQ:LEXX) Frequently Asked Questions

What stocks does MarketBeat like better than Lexaria Bioscience?

Wall Street analysts have given Lexaria Bioscience a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Lexaria Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Lexaria Bioscience?

Lexaria Bioscience saw a increase in short interest in September. As of September 15th, there was short interest totaling 358,900 shares, an increase of 22.4% from the August 31st total of 293,300 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 0.3 days. Approximately 15.0% of the company's stock are short sold.
View Lexaria Bioscience's Short Interest
.

When is Lexaria Bioscience's next earnings date?

Lexaria Bioscience is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Lexaria Bioscience
.

Who are Lexaria Bioscience's key executives?

Lexaria Bioscience's management team includes the following people:
  • Christopher A. Bunka, Chairman & Chief Executive Officer
  • John Martin Docherty, President & Director
  • Gregory John Downey, Chief Financial Officer
  • Ed Ergenzinger, Chief Legal Officer & Senior VP-Innovation

What is Lexaria Bioscience's stock symbol?

Lexaria Bioscience trades on the NASDAQ under the ticker symbol "LEXX."

How do I buy shares of Lexaria Bioscience?

Shares of LEXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexaria Bioscience's stock price today?

One share of LEXX stock can currently be purchased for approximately $6.77.

How much money does Lexaria Bioscience make?

Lexaria Bioscience has a market capitalization of $34.55 million and generates $380,000.00 in revenue each year. The company earns $-4.09 million in net income (profit) each year or ($1.50) on an earnings per share basis.

How many employees does Lexaria Bioscience have?

Lexaria Bioscience employs 3 workers across the globe.

What is Lexaria Bioscience's official website?

The official website for Lexaria Bioscience is www.lexariabioscience.com.

Where are Lexaria Bioscience's headquarters?

Lexaria Bioscience is headquartered at 100 - 740 MCCURDY ROAD, KELOWNA A1, V1X 2P7.

How can I contact Lexaria Bioscience?

Lexaria Bioscience's mailing address is 100 - 740 MCCURDY ROAD, KELOWNA A1, V1X 2P7. The company can be reached via phone at (250) 765-6424 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.